Finding. BRAF-mutant melanoma that has learned to live with MAPK inhibitors still needs the RNA helicase eIF4A to keep translating its survival and metabolic program. Schcolnik-Cabrera, Hulea and colleagues show that several eIF4A inhibitors kill both naive A375 cells and BRAF-inhibitor-resistant A375R cells. CR-1-31-B shuts down new protein, drops BCL-2, CDK4, and cyclin D3, stops colonies, and pushes apoptosis. In resistant cells it does that job beside PLX4032. The metabolic half is mitochondrial: TCA-cycle and pentose-phosphate pools shrink, and glutamine carbon stops moving past uptake. In mice, CR-1-31-B slows A375 tumors; with PLX4720 the control is deeper and lasts longer than BRAF inhibition alone.
Why this paper matters
Resistance mechanisms in melanoma are a catalog. This paper asks whether they share a translation habit. Polysomes, proteomes, and metabolite traces say yes. Resistance is not only more RNA of the right genes. It is translational efficiency and buffering over survival, matrix, plasticity, and mitochondrial functions. eIF4A inhibition hits the proteins that arrived with resistance first, and it does it faster at the ribosome than at steady-state RNA.
The 5′ UTR hint is practical: purine-rich, locally structured leaders on the sensitive set. That is how a helicase inhibitor becomes selective without being a BRAF drug.
Mitochondria as the metabolic receipt
A lower-output metabolic state in both sensitive and resistant cells is the organelle claim. Not “OXPHOS gene set down on a volcano plot.” Smaller TCA and PPP pools. Glutamine comes in; the carbons do not travel. Translation is buying a mitochondrial working set that resistance learned to need. Cut the helicase and that set is unaffordable.
How to read the score
Mid-to-high seventies. Full preclinical stack, a named combo, a mitochondrial-metabolite readout. Confidence is medium: one xenograft line in the abstract, and eIF4A drugs are harsh. This is a rationale to test, not a regimen.
Caveats
A375 is not every resistant patient. Bioenergetic traces are not quantified here. Do not write “eIF4A inhibition reverses melanoma resistance” as a clinical fact.
What to do with it
If you map MAPK-resistance metabolism, add eIF4A as an upstream valve on mitochondrial output. If you mine combo trials, the pair is CR-1-31-B (or its kin) with a BRAF inhibitor. Pull the glutamine-tracer and polysome tables, not just the apoptosis bars.